These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17407648)

  • 1. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.
    Cohen A; Horton ES
    Curr Med Res Opin; 2007 Apr; 23(4):905-17. PubMed ID: 17407648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
    Meece J
    Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.
    Boyle PJ; Freeman JS
    J Am Osteopath Assoc; 2007 May; 107 Suppl():S10-6. PubMed ID: 17724013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs for the treatment of type 2 diabetes.
    Chowdhury TA; Hossain B
    Br J Hosp Med (Lond); 2007 Apr; 68(4):178-83. PubMed ID: 17465090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
    Barnett A; Allsworth J; Jameson K; Mann R
    Curr Med Res Opin; 2007 Jul; 23(7):1493-507. PubMed ID: 17559747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral antidiabetic agents in type 2 diabetes.
    Levetan C
    Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ; Mentlein R
    Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are incretins, and how will they influence the management of type 2 diabetes?
    Blonde L; Rosenstock J; Triplitt C
    J Manag Care Pharm; 2006 Sep; 12(7 Suppl A):S2-12; quiz S14-6. PubMed ID: 16981805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
    Kendall DM; Kim D; Maggs D
    Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.